Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et-Reference-Cited by-同舟云学术

Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et

Published:2018-10-09 Issue:6 Volume:5 Page:1069-1071
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Ramires Felix J.A.¹,Martinez Felipe²,Gómez Efraín A.³,Demacq Caroline⁴,Gimpelewicz Claudio R.⁵,Rouleau Jean L.⁶,Solomon Scott D.⁷,Swedberg Karl⁸⁹,Zile Michael R.¹⁰,Packer Milton¹¹,McMurray John J.V.¹²

Affiliation:

1. Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo; São Paulo Brazil

2. Cordoba National University, Instituto DAMIC/Fundación Rusculleda; Córdoba Argentina

3. Clinica Shaio; Bogotá Colombia

4. Novartis Pharma; São Paulo Brazil

5. Novartis Pharma; Basel Switzerland

6. Institut de Cardiologie de Montréal; Université de Montréal; Montréal Canada

7. Department of Cardiovascular Medicine; Brigham and Women's Hospital; Boston MA USA

8. Department of Molecular and Clinical Medicine; University of Gothenburg; Gothenburg Sweden

9. National Heart and Lung Institute, Imperial College London; London UK

10. Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center; Charleston SC USA

11. Baylor Heart and Vascular Institute; Baylor University Medical Center; Dallas TX USA

12. British Heart Foundation Cardiovascular Research Centre; University of Glasgow; 126 University Place Glasgow G12 8TA UK

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ehf2.12355/fullpdf

Reference9 articles.

1. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial;Bocchi;ESC Heart Fail,2018

2. The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics;Krum;Eur J Heart Fail,2015

3. Angiotensin-neprilysin inhibition versus enalapril in heart failure;McMurray;N Engl J Med,2014

4. Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy;Shen;Circ Heart Fail,2017

5. Chagas cardiomyopathy: clinical presentation and management in the Americas;Benziger;Cardiol Clin,2017

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the Missing Pieces: Exploring the Gaps in Understanding Chagas Cardiomyopathy;Cureus;2024-08-15

2. Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy;JACC: Heart Failure;2024-08

3. Revisión sistemática y metanálisis de la mortalidad en la miocardiopatía chagásica crónica frente a otras miocardiopatías: ¿mayor riesgo o ficción?;Revista Española de Cardiología;2024-05

4. A systematic review and meta-analysis of mortality in chronic Chagas cardiomyopathy versus other cardiomyopathies: higher risk or fiction?;Revista Española de Cardiología (English Edition);2024-03

5. Are patents important indicators of innovation for Chagas disease treatment?;Expert Opinion on Therapeutic Patents;2023-02-15